- Home
- ICG vs DXR Comparison
ICG vs DXR Comparison
Compare ICG & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICG | DXR |
|---|---|---|
| Founded | 2017 | 1970 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 71.4M |
| IPO Year | 2022 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ICG | DXR |
|---|---|---|
| Price | $1.35 | $11.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 52.0K | 11.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $5,805.74 |
| Revenue Next Year | $75.98 | $70.00 |
| P/E Ratio | ★ $6.80 | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $7.10 |
| 52 Week High | $4.19 | $14.76 |
Technical Indicators
Market Signals| Indicator | ICG | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 38.60 |
| Support Level | $1.19 | $11.44 |
| Resistance Level | $1.93 | $14.02 |
| Average True Range (ATR) | 0.11 | 0.40 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 41.84 | 27.03 |
Price Performance
Historical ComparisonAbout ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.